Breaking News Instant updates and real-time market news.

MYOK

MyoKardia

$51.98

-2.33 (-4.29%)

16:01
03/25/19
03/25
16:01
03/25/19
16:01

MyoKardia files to sell $200M in common stock

BofA Merrill Lynch, Credit Suisse, Cowen and Wells Fargo Securities are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.

MYOK MyoKardia
$51.98

-2.33 (-4.29%)

01/03/19
MSCO
01/03/19
NO CHANGE
Target $70
MSCO
Overweight
MyoKardia shares oversold on Sanofi collaboration end, says Morgan Stanley
Morgan Stanley analyst Jeffrey Hung said MyoKardia (MYOK) management emphasized that Sanofi (SNY) wanted greater economics and maintained that efficacy and safety did not factor into Sanofi's decision to end their collaboration. His base case assumption is that MyoKardia will find another partner after more mature data are reported and he thinks the shares have been oversold following yesterday's announcement, Hung tells investors. He trimmed his price target on the stock to $70 from $72, but keeps an Overweight rating, stating that he believes the Phase 2 mavacamten data were promising and sees multiple catalysts over the next year.
01/16/19
CANT
01/16/19
NO CHANGE
Target $90
CANT
Overweight
Cantor reiterates Overweight rating on MyoKardia with $90 target
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on MyoKardia (MYOK) with a $90 price target. The analyst updated her model after MyoKardia partner Sanofi (SNY) decided not to continue the companies' collaboration. Young's model now assumes MyoKardia regaining full global commercial rights to both mavacamten and MYK-491 and also assuming sole responsibility for future development costs. However, her $90 target for MyoKardia shares remains unchanged.
02/21/19
BMOC
02/21/19
INITIATION
BMOC
Outperform
MyoKardia initiated with an Outperform at BMO Capital
BMO Capital analyst George Farmer initiated MyoKardia with an Outperform rating and $85 price target. The analyst said he would be a buyer on his view of the potential of lead drug, mavacamten, for treatment of hypertrophic cardiomyopathy. He added that the recent stock pullback caused by the loss of Sanofi (SNY) as an entrenched partner, which he believes mostly had to do with Sanofi pipeline re-prioritization, creates an attractive entry point for investment in MyoKardia.
03/05/19
BMOC
03/05/19
NO CHANGE
Target $90
BMOC
Outperform
MyoKardia price target raised to $90 from $85 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on MyoKardia to $90 and kept her Outperform rating, saying its latest PIONEER open-label extension results support the mavacamten efficacy and safety in oHCM patients while also posing a "positive read-through to the ongoing Phase 3 EXPLORER trial for oHCM". Bania notes that her new price target reflects a 10% increase in probability of success of mavacamten in oHCM and nHCM to 70% and 50% respectively.

TODAY'S FREE FLY STORIES

SPT

Sprout Social

20:34
12/12/19
12/12
20:34
12/12/19
20:34
Syndicate
Sprout Social 8.824M share IPO priced at $17.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

20:16
12/12/19
12/12
20:16
12/12/19
20:16
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08
Upgrade
Bluebird Bio rating change  »

Bluebird Bio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$6.73

-0.97 (-12.60%)

20:07
12/12/19
12/12
20:07
12/12/19
20:07
Syndicate
Aquestive Therapeutics 7M share Secondary priced at $5.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BY

Byline Bancorp

$18.95

0.54 (2.93%)

19:56
12/12/19
12/12
19:56
12/12/19
19:56
Hot Stocks
Byline Bancorp initiates 3c per share cash dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

NXGN

NextGen Healthcare

$16.83

-1.28 (-7.07%)

19:08
12/12/19
12/12
19:08
12/12/19
19:08
Downgrade
NextGen Healthcare rating change at Cantor Fitzgerald »

NextGen Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMOT

Allied Motion

$46.79

0.81 (1.76%)

18:57
12/12/19
12/12
18:57
12/12/19
18:57
Hot Stocks
Allied Motion CEO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

, DISCA

Discovery

$32.36

0.28 (0.87%)

18:54
12/12/19
12/12
18:54
12/12/19
18:54
Hot Stocks
Liberty Latin America says Dr. John Malone retires from board »

Liberty Latin America…

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

DISCA

Discovery

$32.36

0.28 (0.87%)

LGF.A

Lionsgate

$9.99

0.65 (6.96%)

LGF.B

Lionsgate

$9.35

0.7 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOCPY

Hoya Corp.

$0.00

(0.00%)

, TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

18:43
12/12/19
12/12
18:43
12/12/19
18:43
Hot Stocks
Hoya to offer JPY12,900 per share in tender offer for Toshiba unit NuFlare »

Hoya Corporation (HOCPY)…

HOCPY

Hoya Corp.

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ADBE

Adobe

$305.76

2.01 (0.66%)

, SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:42
12/12/19
12/12
18:42
12/12/19
18:42
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$305.76

2.01 (0.66%)

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

DDOG

Datadog

$35.75

0.23 (0.65%)

RIG

Transocean

$5.94

0.28 (4.95%)

TPR

Tapestry

$26.35

0.515 (1.99%)

GTIM

Good Times Restaurants

$1.71

0.14 (8.92%)

ORCL

Oracle

$56.47

0.16 (0.28%)

AVGO

Broadcom

$327.39

7.53 (2.35%)

COST

Costco

$297.50

2.28 (0.77%)

CNC

Centene

$58.52

-0.13 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 23

    Jan

  • 23

    Mar

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:40
12/12/19
12/12
18:40
12/12/19
18:40
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta up 28.5% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$28.67

0.1 (0.35%)

18:38
12/12/19
12/12
18:38
12/12/19
18:38
Syndicate
Phreesia 6.75M share Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:31
12/12/19
12/12
18:31
12/12/19
18:31
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

18:25
12/12/19
12/12
18:25
12/12/19
18:25
Hot Stocks
Adobe CEO: We are not overly concerned with the trade war with China »

Comment from interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:20
12/12/19
12/12
18:20
12/12/19
18:20
Hot Stocks
Sarepta announces FDA approval of VYONDYS 53 injection to treat DMD »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,760.44

11.33 (0.65%)

18:11
12/12/19
12/12
18:11
12/12/19
18:11
Hot Stocks
Amazon orders fourth season of 'The Marvelous Mrs. Maisel' »

Amazon Studios announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHAI

OHA Investment

$1.28

(0.00%)

, PTMN

Portman Ridge Finance

$2.04

(0.00%)

18:10
12/12/19
12/12
18:10
12/12/19
18:10
Hot Stocks
OHA Investment obtains stockholder approval of Portman Ridge deal »

OHA Investment…

OHAI

OHA Investment

$1.28

(0.00%)

PTMN

Portman Ridge Finance

$2.04

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCT

Oncternal Therapeutics

$4.62

0.05 (1.09%)

18:05
12/12/19
12/12
18:05
12/12/19
18:05
Hot Stocks
Oncternal presents interim data from Phase 1b clinical study of cirmtuzumab »

Oncternal Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$3.49

0.14 (4.18%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Horizon Global CFO Jamie Pierson steps down »

Horizon Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Oracle CEO Catz says expects momentum in 2H20 to carry into FY21 »

Says feels "very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:00
12/12/19
12/12
18:00
12/12/19
18:00
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

17:52
12/12/19
12/12
17:52
12/12/19
17:52
Hot Stocks
Oracle's Ellison says 'we have no plans for having a second CEO' »

Says there won't be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

, EVRC

Evercel, Inc

$0.00

(0.00%)

17:41
12/12/19
12/12
17:41
12/12/19
17:41
Hot Stocks
NewLink Genetics advances over 11% after Evercel discloses rejected offer »

Shares of NewLink…

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

EVRC

Evercel, Inc

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRC

Evercel, Inc

$0.00

(0.00%)

, NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

17:36
12/12/19
12/12
17:36
12/12/19
17:36
Hot Stocks
Evercel announces rejected offer to acquire NewLink Genetics »

Evercel (EVRC) has made…

EVRC

Evercel, Inc

$0.00

(0.00%)

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.30

0.225 (3.70%)

17:34
12/12/19
12/12
17:34
12/12/19
17:34
Hot Stocks
Corsair Capital reports 8.77% passive stake in Baudax Bio »

Corsair Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.